MSA-01

Phase 3Small molecule

TTokyo University

MSA-01 is one of 29 small molecule programs targeting Multiple System Atrophy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple System AtrophyActive, not recruiting

Multiple System AtrophyPhase 3

Active, not recruiting

Competition

Competitive Landscape

48 competitors in Multiple System Atrophy

#DrugCompanyPhaseTrials

Northera

Rifadin

Sudafed

Rilutek

AAzurity Pharmaceuticals

Rifampicin

1 6

Byetta

AstraZeneca

Phase 2

—7

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 2

1 8

Rapamune

PPrism Pharmaceuticals

Phase 2

1 9

Lithobid

SSolvay Pharmaceuticals

Phase 2

1 10

Immunoglobulin

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Recruiting

Multiple System Atrophy

NCT07446894

Clinical

Trials by Indication[1]

Multiple System Atrophy1 trial

MSA-01 in Multiple System Atrophy

Recruiting·TTokyo University·Phase 3·NCT07446894·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MSA-01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MSA-01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MSA-01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tokyo University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTokyo University

MSA-01

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Multiple System Atrophy1 trial

References

Drug Info

Quick Facts

Related News